'Inventor: James Black Alone' is Incorrect — ICI's β-Blocker Patent US3408387A Was Invented by Howe & Smith, and the Propranolol Core Patent US3337628A by Crowther & Smith. Black Won the 1988 Nobel Prize but Is Not Named on Either ICI Patent

About excavation memos: "Excavation memos" in this series record candidate summaries at the stage where the primary-source URL has been confirmed. Full-text reading and verbatim verification of all claims have not been performed. Only confirmed facts are recorded; speculation is explicitly marked.

Why dig

β-adrenergic receptor blockers (β-blockers) symbolize the 1960s paradigm shift in cardiovascular pharmacology. The concept itself — "designing drugs to target a receptor" — was new at the time, and James Whyte Black's systematic β-blocker exploration at the Imperial Chemical Industries (ICI) research lab, together with the later H2 receptor blocker (cimetidine, SmithKline & French, 1976), formed the basis of his 1988 Nobel Prize in Physiology or Medicine.

The textbook narrative widely circulates the simplification "James Black invented β-blockers," but checking patent inventor fields, Black's name barely appears. Black directed research as ICI's Research Director while patent filings were handled by chemists — Albert Frederick Crowther, Ralph Howe, Leslie Harold Smith — who performed chemical synthesis in a divided-labor structure.

The DB row PH-005 in ~/ai-archaeology/db/candidates.tsv lists "β-blocker propranolol patent US3408387A" with "inventor: James W. Black," but the primary sources confirmed on Google Patents show the following structural facts:

1. DB-registered US3408387A: Title "Amidoaroxyalkanolamines," inventors "Ralph Howe / Leslie Harold Smith" (two co-inventors, no Black), assignee ICI, priority 1964-09-30, filed 1965-09-17, granted 1968-10-29, expired 1985-10-29. This is a derivative series patent within ICI's β-blocker exploration program.
2. Propranolol core patent US3337628A: Title "3-naphthyloxy-2-hydroxypropylamines," inventors "Albert Frederick Crowther / Leslie Harold Smith" (two co-inventors, no Black), assignee ICI, priority 1962-11-23, filed 1963-11-12, granted 1967-08-22. The substance patent covering propranolol's chemical backbone (1-isopropylamino-3-(1-naphthoxy)-2-propanol), with Claim 1 asserting the naphthyloxy-propanolamine compound class.

Black is not named as an inventor on either patent, reflecting (a) ICI's patent-filing policy (the convention of listing chemists who performed chemical synthesis as inventors), (b) the divided-labor structure where Black directed overall research as Research Director without directly engaging in specific compound synthesis, and (c) inventor-recognition standards at 1960s UK research institutions.

Patent basic information

DB-registered derivative series patent US3408387A

• Patent number: US3408387A
• Title: Amidoaroxyalkanolamines
• US filing date: September 17, 1965
• US priority date: September 30, 1964
• US grant date: October 29, 1968
• Inventors: Ralph Howe / Leslie Harold Smith (two co-inventors, the DB record listing "James W. Black" is incorrect)
• Original Assignee: Imperial Chemical Industries Ltd
• Current Assignee: Imperial Chemical Industries Ltd
• US expiration: October 29, 1985 (17 years from grant)
• Primary source: Google Patents (URL confirmed; title, full Claim 1, two inventors, filing/grant dates, assignee — all retrieved)

Propranolol core patent US3337628A

• Patent number: US3337628A
• Title: 3-naphthyloxy-2-hydroxypropylamines
• US filing date: November 12, 1963
• US priority date: November 23, 1962
• US grant date: August 22, 1967
• Inventors: Albert Frederick Crowther / Leslie Harold Smith (two co-inventors, no Black)
• Original Assignee: Imperial Chemical Industries Ltd
• Current Assignee: Imperial Chemical Industries Ltd
• Primary source: Google Patents (URL confirmed; title, two inventors, filing/grant dates, assignee — all retrieved)

Core (Google Patents retrieved information)

US3408387A Claim 1 reads:

An alkanolamine derivative selected from the group consisting of compounds of the formula [...] wherein R is alkyl of up to 12 carbon atoms, hydroxyalkyl of up to 12 carbon atoms, alkyl substituted by alkoxy or aryloxy, cycloalkyl of up to 8 carbon atoms, alkenyl of up to 6 carbon atoms, or alkyl substituted by phenyl or halogenophenyl; [...] and the pharmaceutically acceptable acid addition salts thereof.

The backbone is the "amidoaroxyalkanolamine" class — alkanolamine derivatives of an aroxy backbone with an amide linkage on the benzene ring. This is a derivative series with a different aromatic-ring structure from the propranolol core (naphthyloxy-propanolamine), likely used in the exploration of later β1-selective blockers (atenolol, metoprolol, etc.).

US3337628A's Claim 1 covers compounds centered on the "naphthyloxy-2-hydroxypropylamine" backbone, directly covering propranolol (1-isopropylamino-3-(1-naphthoxy)-2-propanol). Propranolol itself is described as an exemplary compound in the specification, with Claim 1 covering the general compound class as a substance patent.

ICI's β-blocker development followed this timeline:

• 1958: James Black joined ICI's research lab and began β-blocker exploration
• Early 1960s: Pronethalol (Alderlin) developed, UK-approved 1962, but withdrawn 1963 due to carcinogenicity in animal studies
• 1962: Propranolol discovered, ICI filed patent with priority 1962-11-23 (US3337628A's priority date)
• 1965: UK approval of propranolol (Inderal brand)
• 1967: US FDA approval, US patent US3337628A granted
• 1964-1968: Derivative series patents (including US3408387A) filed and granted in succession
• 1988: James Black received the Nobel Prize in Physiology or Medicine (for β-blockers and cimetidine H2 blocker)

Modern correspondence (includes speculation)

A note on how to read this correspondence table.

Rows 1-3 are identical. The "design drugs targeting receptors" concept was systematized by Black in the 1960s and is inherited as the core methodology for modern GPCR drug discovery (β-blockers, ARBs, antihistamines, SSRIs, opioids, etc.). β1-selective blockers derived from propranolol are direct development lineage, sharing chemical backbone while improving receptor selectivity.

Row 4 is identical. Propranolol started in 1965 with three indications (hypertension, angina, arrhythmia) and continuously expanded to (i) heart failure (established with β1-selective blockers, carvedilol approved 1995), (ii) hyperthyroidism symptom relief, (iii) migraine prophylaxis (propranolol FDA indication added 1979), (iv) essential tremor, (v) public-speaking anxiety.

Row 5 is similar. ICI was a mid-20th-century integrated chemical company spanning pharma, agrochemicals, dyes, fibers, etc., but spun off pharma/agrochem as Zeneca in 1993, merging into AstraZeneca in 1999. The "integrated chemicals → pharma specialization" flow occurred in parallel at Hoechst (via Aventis to Sanofi merger), Bayer (pharma division independence), Roche, Novartis — late-20th-century industry restructuring.

Row 6 is identical. The convention of "naming chemists who performed chemical synthesis as inventors on patents" continues today. Research directors, division heads, and executives typically don't appear in inventor fields. This is consistent with the patent-law definition of "inventor" (natural persons who actually made inventive contributions). Black is not named on either patent because he directed overall research direction as ICI's Research Director without directly performing specific synthetic or experimental innovations.

Row 7 is similar. In modern pharma research labs, team leaders direct research direction while synthesis chemists and pharmacologists make individual inventive contributions in a divided-labor structure that continues today. Academic evaluations like the Nobel Prize evaluate contributions to overall research, so they don't align with patent inventors.

Row 8 is metaphorical. The Nobel Prize evaluates "contributions to overall research" while patents evaluate "specific inventive contributions" — different axes. Black's 1988 Nobel reasoning was "principles of drug treatment," combining β-blockers and cimetidine H2 blocker work. Black's absence from propranolol patent inventor fields and his Nobel Prize are compatible facts.

Why is it worth digging? (speculation)

Reason 1: Divergence between "Black sole inventor" narrative and patent history

Textbooks and general-audience books circulate the simplified narrative "James Black invented β-blockers and won the Nobel Prize." In reality, ICI teamwork (synthesis chemists Crowther / Howe, medicinal chemist Smith, pharmacologist Black) drove development through divided labor, and Black's name does not appear on patent inventor fields. This divergence stems from the structural difference between "Nobel Prize evaluation axis" and "patent-law inventor recognition" and is inherited by modern pharma research. General technology discourse tends to simplify "Nobel Prize = inventor," but patent history records on a separate axis.

Reason 2: 1960s UK patent-filing policy

ICI filed many pharma patents in the 1960s, establishing the convention of naming chemists who performed chemical synthesis as inventors. Research directors and pharmacologists like Black, unless directly involved in synthetic innovations, did not enter inventor fields. This convention is consistent with US, UK, and Japanese patent law, but differs from US universities (especially cases where research-supervising professors are named as inventors) where research directors are named as contributors. Japan's pharma industry follows ICI's UK convention closely, with chemist-centered inventor recognition as standard.

Reason 3: Starting point of modern β-blocker indication expansion

Propranolol's core patent US3337628A (priority 1962) expired in the US in the 1980s, but β-blockers as an indication class are still actively used in cardiovascular, metabolic, and neurological domains. From the 1965 approval indications (hypertension, angina, arrhythmia), expansion to heart failure, migraine prophylaxis, essential tremor, hyperthyroidism symptom relief, and public-speaking anxiety has continued for 60 years. This is a typical example of "drug class expansion via indication expansion after patent expiration."

Pitfalls

Pitfall 1: "Black invented β-blockers" is an oversimplification

Black directed the β-blocker exploration program direction as ICI's Research Director, but synthesis chemists Crowther, Howe, and medicinal chemist Smith handled propranolol (compound ICI 45520) and derivative compound synthesis and optimization. "Inventor" in patent law refers to natural persons who made synthetic or experimental innovations, typically excluding research directors. "Black invented β-blockers" is historically correct as a research program leader, but inaccurate as patent history.

Pitfall 2: "DB number US3408387A is the propranolol core patent" is incorrect

The DB-registered US3408387A is the "Amidoaroxyalkanolamines" (amidoaroxyalkanolamine) series, with a different aromatic-ring structure from propranolol's core (naphthyloxy-propanolamine) — a derivative series. Propranolol's core patent is US3337628A (priority 1962, granted 1967, Crowther & Smith). The DB number likely confused derivative and core when arc-quoting from secondary sources (same pattern as Day 11 PH-007).

Pitfall 3: "Propranolol = mainstream modern β-blocker" is incorrect

Propranolol is a non-selective (β1 + β2 + partial β3) blocker with side effects from β2 blockade (bronchoconstriction, peripheral vasoconstriction). Modern cardiovascular practice uses β1-selective blockers (atenolol 1976, metoprolol 1978, bisoprolol 1986) and α/β blockers (carvedilol 1995) as mainstream. Propranolol is still prescribed for specific indications (migraine prophylaxis, essential tremor, public-speaking anxiety), but is not the first-choice cardiovascular drug.

Pitfall 4: "Black's Nobel Prize was for β-blockers alone" is an oversimplification

The 1988 Nobel Prize in Physiology or Medicine was jointly awarded to James W. Black (ICI, β-blockers) and Gertrude B. Elion / George H. Hitchings (Burroughs Wellcome, antiviral and anticancer drugs), reasoning "important principles for drug treatment." Black's achievements were evaluated combining ICI-era β-blockers (propranolol) and SmithKline & French-era H2 receptor blockers (cimetidine, Tagamet brand, approved 1976). "Nobel Prize = β-blockers" is an oversimplification — Black's entire research life (establishing the methodology of receptor-targeting drugs) was the evaluation target.

Strictly speaking

Confirmed facts

From Google Patents (DB-registered derivative series): US3408387A / Title "Amidoaroxyalkanolamines" / Inventors "Ralph Howe / Leslie Harold Smith" two co-inventors (the DB record listing "James W. Black" is incorrect) / Original Assignee "Imperial Chemical Industries Ltd" / Current Assignee "Imperial Chemical Industries Ltd" / Priority date 1964-09-30 / Filing date 1965-09-17 / Grant date 1968-10-29 / Expiration 1985-10-29 / Full Claim 1 retrieved (with description of β-adrenergic blocking activity)

From Google Patents (propranolol core): US3337628A / Title "3-naphthyloxy-2-hydroxypropylamines" / Inventors "Albert Frederick Crowther / Leslie Harold Smith" two co-inventors (no Black) / Original Assignee "Imperial Chemical Industries Ltd" / Current Assignee "Imperial Chemical Industries Ltd" / Priority date 1962-11-23 / Filing date 1963-11-12 / Grant date 1967-08-22

1988 Nobel Prize in Physiology or Medicine: James W. Black / Gertrude B. Elion / George H. Hitchings jointly awarded, reasoning "important principles for drug treatment" (Nobel Prize official nobelprize.org/prizes/medicine/1988/summary/).

Author's interpretation "Black not named on either patent reflects ICI's patent-filing policy" and "Nobel Prize evaluation axis differs from patent inventor axis" are author interpretations. The exact policy document of inventor recognition inside ICI is not retrieved within this article's scope. Black's autobiography/biography (Drug Discovery: A Casebook and Analysis, etc.) may describe inventor recognition history.

Metaphors / analogies Row 5 (ICI integrated chemicals → Zeneca pharma specialization industry restructuring) is similar. Hoechst / Bayer / Roche / Novartis parallel examples advanced pharma specialization in the late 20th century, but each company's path differs. Row 7 (Black's Research Director leadership → modern pharma research lab team-leader model) is similar. Leadership structure continues but inventor recognition is on separate axis. Row 8 (Nobel Prize vs patent inventors) is metaphorical. Different evaluation axes, so they coexist.

Not confirmed Full text of US3408387A / US3337628A Description sections, verbatim / Synthesis records and internal research records of propranolol (compound ICI 45520) / James Black's autobiography/biography descriptions of inventor recognition history / Internal records of pronethalol (Alderlin) withdrawal / 1965 UK / 1967 US propranolol approval clinical trial data / 1988 Nobel Prize selection committee internal documents / Patents and inventor structures of derivative β1-selective blockers (atenolol ICI 1976, etc.) / Detailed history of propranolol's migraine prophylaxis and essential tremor indication expansion

Where this comparison breaks down US3408387A is the "Amidoaroxyalkanolamines" derivative series, with a different aromatic-ring structure from propranolol's core (naphthyloxy-propanolamine). Both patents are ICI-assigned with descriptions of β-adrenergic blocking activity, but the DB record stating "DB-registered number is propranolol core" is structurally incorrect (same pattern as Day 11 PH-007). This article additionally covers the core patent US3337628A for correction. The "Black sole inventor" narrative simplification still circulates in media and textbooks, and whether this article's patent-history correction permeates general technology discourse is a separate matter. The excavation memo is limited to confirmation within Google Patents — full Description text, ICI internal materials, Black autobiography, comprehensive coverage of derivative β-blocker patents, and detailed indication expansion history are not retrieved, and this is explicitly noted.

Reference links:

• DB-registered derivative series patent: US3408387A on Google Patents
• Propranolol core patent: US3337628A on Google Patents
• 1988 Nobel Prize official: The Nobel Prize in Physiology or Medicine 1988
• Related Excavation Note (Pharma Patents #1): Cetus PCR core patent US4683195A (1985)
• Related Excavation Note (Pharma Patents #2): Köhler & Milstein monoclonal antibody (1975 Nature) + Wistar US4172124A
• Related Excavation Note (Pharma Patents #3): Squibb Ondetti & Cushman ACE inhibitor (captopril) two-series patents
• Related Excavation Memo #1 (Pharma Patents): Akira Endo statin core patent US4049495A (1974 priority)
• Related Excavation Memo #2 (Pharma Patents): Banting/Best/Collip insulin US1469994 (1923, UoT+UAlberta joint assignment)